The shelf being effective means Dermata can conduct an underwritten offering at any time. Given the company's micro-cap status and the massive $100M shelf relative to its market cap, the overhang is severe. Traders should watch for a prospectus supplement (424B5) indicating an actual takedown — that event would likely drive DRMA and DRMAW sharply lower. Until then, the overhang alone should cap any upside.
Price Chart
Executive Summary
The SEC declared effective Dermata Therapeutics' S-3 shelf registration (File No. 333-291740) on May 29, 2026, allowing the company to offer and sell up to $100,000,000 in common stock, preferred stock, warrants, debt securities, subscription rights, and units from time to time. This creates a significant dilution overhang for the company's common stock and warrants (DRMA/DRMAW), as the shelf can be drawn down at management's discretion without further shareholder approval.
Key Facts
- Effectiveness date: May 29, 2026
- Shelf registration amount: $100,000,000
- Securities registered: common stock, preferred stock, warrants, debt securities, subscription rights, units
- Company's common stock last traded at $1.24/share and warrants at $0.0139/warrant on May 21, 2026
- This is a new shelf (File No. 333-291740), separate from the January 2026 S-3 resale shelf (File No. 333-291740 was the new shelf; the January S-3 had a different file number)
Financial Impact
Up to $100,000,000 in potential dilution — at the current $1.24 common stock price, this represents approximately 80.6 million shares of potential dilution, dwarfing the current market cap.
Risk Factors
- Imminent dilutive offering — the company has a history of using shelf registrations to raise capital
- Warrant holders (DRMAW) face extreme dilution risk as any common stock offering would further depress the already low $0.0139 warrant price
- No disclosed use of proceeds — typical for a general shelf, but suggests capital raise is likely given the company's cash needs as a clinical-stage biotech
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001810 |
| Document: 9999999995-26-001810-index.html | 9999999995-26-001810 |
| Document: 9999999995-26-001810.txt | 9999999995-26-001810 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 1, 2026 21w ago | EFFECT | $0.0183 $0.0103 | ▲ +43.72% | ▲ +42.42% | — |
May 27, 2026 21w ago | 8-K | $0.0183 $0.0183 | · 0.00% | ▲ +2.44% | — |
Apr 17, 2026 27w ago | DEFA14A | $0.0183 $0.0183 | · 0.00% | ▼ −4.20% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers